Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
Por:
Antolín-Novoa S, Blanco-Campanario E, Antón A, Gallegos-Sancho MI, Pérez-Carrión R, Peláez I, Galán-Brotons A, de la Cruz-Merino L and Murías-Rosales A
Publicada:
1 nov 2015
Ahead of Print:
24 jun 2015
Resumen:
Trastuzumab has proven to improve the prognosis of HER2-positive breast
cancer, but the information available about its administration for small
tumors is still limited. Therefore, we assessed the use of adjuvant
regimens with trastuzumab for the treatment of small HER2-positive
breast cancer in routine clinical practice.
This observational study was conducted in patients with HER2-positive
breast adenocarcinoma a parts per thousand currency sign1.5 cm who
received trastuzumab-based adjuvant treatment in clinical practice.
Clinical/histopathological data were retrieved from patients' medical
charts.
A total of 101 evaluable patients were enrolled (median age [range],
56.7 [49.0-64.8] years; ECOG 0, 98.0 %; ductal carcinoma, 88.1 %;
lymph nodes N0, 79.2 %). Only five (5.0 %) patients received
neoadjuvant treatment, while all patients underwent tumor surgery.
Adjuvant trastuzumab was administered at a mean (+/- SD) dose of 5.9 +/-
A 1.5 mg/kg/cycle, and mostly in a three-weekly schedule (89 [89.0 %]
patients). The most frequent adjuvant therapy used with trastuzumab was
chemotherapy (87 [86.1 %] patients), followed by radiotherapy (63
[62.4 %] patients) and hormone therapy (52 [51.5 %] patients).
Chemotherapy regimens mainly included doxorubicin, cyclophosphamide and
paclitaxel/docetaxel (n = 30), docetaxel and cyclophosphamide (n = 15),
docetaxel and carboplatin (n = 13). Hormone therapy mainly included
letrozole (n = 17) and tamoxifen (n = 17). Nine (8.9 %) patients
reported trastuzumab-related adverse events; only one allergic reaction
reached grade 3 toxicity.
This study shows that trastuzumab-based adjuvant treatment of small
HER2-positive breast cancer is mostly based on chemotherapy-mainly
paclitaxel/docetaxel. Adjuvant administration of trastuzumab for small
HER2-positive breast cancer seems to be similar to that used for larger
tumors.
|